View Older Stories View More Recent Stories

Aug 18, 2023 06:46AM Merck (MRK) Reports WELIREG Phase 3 LITESPARK-005 Trial Met Primary Endpoint
Aug 18, 2023 06:45AM Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
Aug 8, 2023 04:01PM Ligand Reports Second Quarter 2023 Financial Results
Aug 7, 2023 08:30AM Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial
Aug 3, 2023 06:45AM Merck (MRK) Announces FDA Approval of ERVEBO for Use in Children 12 Months of Age and Older
Aug 3, 2023 06:45AM U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older
Aug 1, 2023 06:30AM Merck Announces Second-Quarter 2023 Financial Results
Aug 1, 2023 05:57AM Busy earnings day, Meta reportedly prepares AI chatbot - what's moving markets
Jul 28, 2023 06:45AM Merck (MRK) Reports Phase 3 KEYNOTE-756 Trial Met Primary Endpoint
Jul 28, 2023 06:45AM Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer
Jul 27, 2023 06:45AM Merck (MRK) Announces V116 Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
Jul 27, 2023 06:45AM Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
Jul 26, 2023 06:45AM Merck (MRK) and Moderna (MRNA) Initiate Phase 3 Study Evaluating V940 in Combination with KEYTRUDA
Jul 26, 2023 06:45AM Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
Jul 25, 2023 12:58PM Merck Announces Fourth-Quarter 2023 Dividend
Jul 21, 2023 07:52AM Merck (MRK) Receives Positive European Union CHMP Opinion for Gefapixant
Jul 21, 2023 07:52AM Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinom
Jul 21, 2023 07:52AM Merck Receives Positive European Union CHMP Opinion for Gefapixant
Jul 21, 2023 07:50AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) A
Jul 19, 2023 06:46AM Merck (MRK) Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS)
Jul 19, 2023 06:45AM Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Jul 17, 2023 08:45AM Argus adds Adobe (ADBE), Merck (MRK), Tesla (TSLA), Walmart (WMT) to its Focus List
Jul 12, 2023 11:30AM MilliporeSigma Invests $25 Million to Expand Cell Culture Media Production in Kansas
Jul 11, 2023 09:05AM Athinia™ expands partnerships to include Tokyo Electron for real-time collaborative analytics of semiconductor fab equipment performance
Jun 29, 2023 06:45AM Merck to Hold Second-Quarter 2023 Sales and Earnings Conference Call on Aug. 1
Jun 20, 2023 06:47AM Merck (MRK) Provides Update on Phase 3 KEYNOTE-585 Trial
Jun 20, 2023 06:45AM Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Jun 16, 2023 04:04PM Merck (MRK) Completes Acquisition of Prometheus Biosciences (RXDX)
Jun 16, 2023 04:04PM Merck Completes Acquisition of Prometheus Biosciences, Inc.
Jun 16, 2023 06:45AM Merck (MRK) Reports KEYTRUDA Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesopha
Jun 16, 2023 06:45AM KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophage
Jun 13, 2023 04:05PM U.S. District Court for the District of New Jersey Rules in Favor of Merck in Patent Infringement Lawsuit Related to BRIDION® (sugammadex)
Jun 12, 2023 06:45AM Merck to Present Data for Efinopegdutide (MK-6024), an Investigational GLP-1/Glucagon Receptor Co-agonist, in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) at EASL 2023
Jun 8, 2023 06:46AM Merck (MRK) Announces FDA Acceptance of Application for KEYTRUDA Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer
Jun 8, 2023 06:45AM FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer
Jun 6, 2023 08:00AM MilliporeSigma Announces Proteologix as Winner of its North American Advance Biotech Grant
Jun 6, 2023 06:51AM Merck (MRK) Announces FDA Approval of New Indication for PREVYMIS for CMV Disease in High-Risk Adult Kidney Transplant Recipients
Jun 6, 2023 06:50AM U.S. FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients
Jun 6, 2023 06:45AM Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
Jun 5, 2023 08:01AM Moderna (MRNA) and Merck (MRK) Announce mRNA-4157 in Combination With KEYTRUDA Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Pat
Jun 3, 2023 09:00AM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemothe
Jun 3, 2023 08:00AM KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma
Jun 1, 2023 07:03AM AstraZeneca (AZN) and Merck (MRK) Announce LYNPARZA plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
Jun 1, 2023 06:45AM Merck (MRK) Announces FDA Approval of LYNPARZA Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated mCRPC
Jun 1, 2023 06:45AM FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
May 25, 2023 05:02PM Merck (MRK) Reports KEYTRUDA Plus LENVIMA Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
May 25, 2023 05:00PM KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
May 23, 2023 02:45PM Merck Announces Third-Quarter 2023 Dividend
May 18, 2023 08:00AM Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer
May 15, 2023 06:45AM Merck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting
View More Recent Stories View Older Stories